Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | ACACB | O00763 | 3/20 | 0.49 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | ACHE | P22303 | 1/20 | 0.48 |
| ▸ | JUN | P05412 | 1/20 | 0.47 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2106645 | 1.00 | HPGD (0.54) | HPGDSMN1; SMN2TSHRLMNAACACB | |
| SCHEMBL1753779 | 0.84 | ACACB (0.51) | HPGDACACB | |
| SCHEMBL24349245 | 0.83 | TSHR (0.58) | SMN1; SMN2TSHRNR3C1ACHEJUN | |
| SCHEMBL19789855 | 0.81 | POLB (0.54) | HPGDSMN1; SMN2LMNAACACB | |
| SCHEMBL15052901 | 0.81 | HPGD (0.56) | HPGDSMN1; SMN2LMNAACACBALDH1A1 | |
| SCHEMBL10148400 | 0.79 | TSHR (0.54) | SMN1; SMN2TSHRLMNANR3C1CA1 | |
| SCHEMBL31500690 | 0.78 | HPGD (0.63) | HPGDSMN1; SMN2CA1CA2ACHE | |
| SCHEMBL27493711 | 0.78 | HPGD (0.63) | HPGDSMN1; SMN2CA1CA2ACHE | |
| SCHEMBL31500691 | 0.78 | HPGD (0.63) | HPGDSMN1; SMN2CA1CA2ACHE | |
| SCHEMBL4964245 | 0.78 | TSHR (0.57) | SMN1; SMN2TSHRNR3C1ACHEJUN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8158650-B2 | Substituted phenylmethyl bicyclocarboxyamide compounds | PFIZER INC. (US) | 2012-04-17 | — | — | US | disclosed |
| EP-2222631-B1 | SUBSTITUTED PHENYLMETHYL BICYCLOCARBOXYAMIDE COMPOUNDS | PFIZER (US) | 2011-08-17 | — | — | EP | disclosed |
| US-20100087480-A1 | SUBSTITUTED PHENYLMETHYL BICYCLOCARBOXYAMIDE COMPOUNDS | PFIZER INC. | 2010-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087480-A1 | SUBSTITUTED PHENYLMETHYL BICYCLOCARBOXYAMIDE COMPOUNDS | TRPV1, P2RY1, TRPV2 | HPGD 1716/4885SMN1; SMN2 1125/4885TSHR 3148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.